Formulary

Employer Utilization Management Tactics Place Healthcare Benefits Cost Before Patient Care, Survey Finds

Retrieved on: 
Wednesday, April 13, 2022

NEW YORK, April 13, 2022 /PRNewswire/ -- Utilization management (UM) tools may be effective in controlling short-term organizational costs, but they are not as effective in controlling health care costs for employees and can even serve as barriers to treatment, according to a new survey of large employers by CancerCare, the leading national cancer support organization.

Key Points: 
  • They overwhelmingly (98%) said that direct costs are the most important information source in their benefits decision making.
  • "When cost is the dominant factor in guiding employers' benefits decision making, employee health can pay the price," said Patricia J. Goldsmith,Chief Executive Officer, CancerCare.
  • "Employers must take care to balance cost savings with the real needs of their employees, especially those with serious or chronic illnesses."
  • A total of 50 executives who are responsible for employee benefits, from 50 different large US employers, participated in the January 2022 CancerCare Employer Market Survey.

Xevant Announces Five Additions to Its Senior Leadership Team

Retrieved on: 
Tuesday, April 12, 2022

Xevant CEO Brandon Newman commented on the additions stating, "We are fortunate to add these five key players to our leadership team who bring 80+ years of combined experience to Xevant.

Key Points: 
  • Xevant CEO Brandon Newman commented on the additions stating, "We are fortunate to add these five key players to our leadership team who bring 80+ years of combined experience to Xevant.
  • Ashwin (Ash) Patel has 20 years of leadership experience in data warehousing and business intelligence practices within the healthcare sector.
  • At Xevant, Ash leads the data and business intelligence teams and is responsible for future state expansion of Xevant data technology platforms and processes.
  • As VP of Sales, Greg leads the Xevant sales team with a motivation to grow revenue and expand market reach.

Avicanna Announces Closing of Non-Brokered Private Placement

Retrieved on: 
Thursday, March 31, 2022

TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a non-brokered private placement offering of 7,210,194 ‎‎units of the Company (the “Units”) at a price of $0.35 per Unit for aggregate gross proceeds of approximately $2.5 million (the “Offering”). Each Unit is comprised of one common share in the capital of the Company (each, a “Unit Share”) and one-half of one (0.5) common share purchase warrant of the Company (each whole warrant, a “Warrant”); and, each Warrant shall entitle the holder thereof to acquire one (1) common share in the capital of the Company at an exercise price of $0.40 per share, subject to adjustment in certain events, until March 31, 2025.

Key Points: 
  • The Unit Shares and Warrants, and any securities issuable upon conversion or exercise thereof, are subject to a four-month hold period under applicable securities laws in Canada.
  • Avicanna is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments.
  • In leading global cannabinoid advancements, the Company actively collaborates with leading Canadian academic and medical institutions.
  • For more information about Avicanna, visit www.avicanna.com, contact Ivana Maric by email at [email protected] or follow us on social media on LinkedIn , Twitter , Facebook or Instagram .

Pear Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Monday, March 28, 2022

In this hypothetical scenario, Pear has 50 filled prescriptions, of which 25 are paid.

Key Points: 
  • In this hypothetical scenario, Pear has 50 filled prescriptions, of which 25 are paid.
  • Pear continued to aggregate digital therapeutics and digital biomarkers in the service of creating the industrys first comprehensive PDT platform.
  • Pear also executed a portfolio of in-licensing deals involving digital biomarkers assessing voice and keystroke, along with wearables and ingestible sensor technologies.
  • On March 24, 2022, Pear announced its PearConnect platform is available to healthcare providers in the Epic App Orchard Gallery.

New Research Shows Consumers Highly Value Broad Product Choice and Provider Expertise in Health Plan Hearing Benefits

Retrieved on: 
Monday, March 28, 2022

Hearing benefits that include access to an extensive hearing aid formulary can play a significant role in ensuring the satisfaction of health plan members, according to two new nationwide surveys of consumers and hearing care providers conducted by Amplifon Hearing Health Care.

Key Points: 
  • Hearing benefits that include access to an extensive hearing aid formulary can play a significant role in ensuring the satisfaction of health plan members, according to two new nationwide surveys of consumers and hearing care providers conducted by Amplifon Hearing Health Care.
  • The survey of 602 consumers, conducted by an independent global market research firm, indicated overall positive feelings about experiences with hearing care providers.
  • Amplifon Hearing Health Care commissioned The Marketing Audit, an independent global market research firm, to conduct surveys of consumers and hearing care providers nationwide.
  • Amplifon Hearing Health Care connects people and resources to improve the lives of people with hearing loss by partnering with health care organizations to administer hearing benefits.

United States Pharmacy Benefit Management Services Procurement Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 24, 2022

The "Pharmacy Benefit Management Services in the US - Procurement Research Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmacy Benefit Management Services in the US - Procurement Research Report" report has been added to ResearchAndMarkets.com's offering.
  • This report is intended for buyers with fully funded insurance and is not tailored to self-insured employers.
  • Common buyers of PBM services include health insurance carriers, pharmacies, and healthcare facilities.
  • A pharmacy benefit management (PBM) provider is a third-party company that manages the sale and distribution of government and employer-sponsored prescription drugs.

Magellan Rx Management Achieves Perfect CMS Audit for Medicare Part D

Retrieved on: 
Monday, March 14, 2022

Magellan Health, Inc. today announced that Magellan Rx Management (MRx), the full-service pharmacy benefit management division of the company, received a perfect audit score from the Centers for Medicare & Medicaid Services (CMS) for its Granite Alliance Insurance Company Employer Group Waiver Plan (EGWP), a type of Medicare Prescription Drug (Part D) plan.

Key Points: 
  • Magellan Health, Inc. today announced that Magellan Rx Management (MRx), the full-service pharmacy benefit management division of the company, received a perfect audit score from the Centers for Medicare & Medicaid Services (CMS) for its Granite Alliance Insurance Company Employer Group Waiver Plan (EGWP), a type of Medicare Prescription Drug (Part D) plan.
  • It is truly remarkable to see zero conditions, zero observations, and a glowing review from CMS across all areas that were audited - CDAG, Formulary Administration, and Compliance Program Effectiveness, said Mostafa Kamal, chief executive officer at Magellan Rx Management.
  • Im incredibly proud of our team and their daily commitment to support the Medicare beneficiaries that our clients entrust us with, and this CMS audit result is further validation of Magellan Rx Managements relentless pursuit of excellence.
  • About Magellan Rx Management: Magellan Rx Management , a division of Magellan Health, Inc. , is a next-generation pharmacy organization that is delivering meaningful solutions to the people we serve.

Big Health Adds Former FDA Deputy Commissioner Anand Shah to Its Board of Directors

Retrieved on: 
Wednesday, January 26, 2022

Big Health , a digital therapeutics company dedicated to helping millions back to good mental health, today announced that it has added former Food and Drug Administration (FDA) Deputy Commissioner for Medical and Scientific Affairs Dr. Anand Shah to its Board of Directors.

Key Points: 
  • Big Health , a digital therapeutics company dedicated to helping millions back to good mental health, today announced that it has added former Food and Drug Administration (FDA) Deputy Commissioner for Medical and Scientific Affairs Dr. Anand Shah to its Board of Directors.
  • As a member of the Big Health Board of Directors, Dr. Shah will help expand access to digital therapeutics as non-drug alternatives for mental health care.
  • We are extremely excited to welcome Dr. Shah to the Big Health Board of Directors to champion the expanded adoption of digital therapeutics.
  • I am honored to join Big Healths Board of Directors to advance their mission of helping millions back to good mental health.

Big Health Raises $75 Million in Series C Funding Led by SoftBank Vision Fund 2

Retrieved on: 
Wednesday, January 19, 2022

As the prevalence of mental health conditions continues to rise , mental health providers cannot meet the scale of demand through in-person or teletherapy alone.

Key Points: 
  • As the prevalence of mental health conditions continues to rise , mental health providers cannot meet the scale of demand through in-person or teletherapy alone.
  • We are proud to announce our Series C funding, which will further fuel our growth and the mass adoption of digital therapeutics.
  • "We believe Big Health is leading the way in bringing evidence-based, effective, low-cost mental health care to millions via their smartphone.
  • Big Health is directly addressing the mental health crisis at scale using digital therapeutics, said Big Health Executive Chairman Arun Gupta.

Meta Technologies Empowers Private Healthcare with Myriad Health

Retrieved on: 
Monday, January 10, 2022

Meta Technologies is introducing the very first completely free EHR and billing software, Myriad Health , to help private practices thrive in the age of corporate medicine.

Key Points: 
  • Meta Technologies is introducing the very first completely free EHR and billing software, Myriad Health , to help private practices thrive in the age of corporate medicine.
  • Myriad Health by Meta Technologies is here to disrupt the status quo and minimize instances of and the need for corporate takeover in private medicine.
  • Meta Technologies capitalized on its background in the healthcare payment space while designing Myriad Health to guarantee payment at the time of treatment and any balance left by insurance.
  • Meta Technologies, Myriad Health and MediPay Compliance Consultants are trademarks of Meta Technologies, Inc. or its reserved subsidiaries.